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The placenta produces a number of signaling molecules including metabolic and reproductive hormones as well as several
inflammatory mediators. Among them, Interleukin-6 (IL-6), a well-known immune and metabolic regulator, acts peripherally
modulating metabolic function and centrally increasing energy expenditure and reducing body fat. IL-6 interacts with key
hypothalamic neuropeptidergic systems controlling energy homeostasis such as those producing the orexigenic/anabolic:
neuropeptide Y (NPY) and agouti-related peptide (AgRP) and anorectic/catabolic neuropeptides: proopiomelanocortin (POMC)
and cocaine and amphetamine regulated transcript (CART). Human and rat placenta have been identified as source of these
neuropeptides, but their expression and regulation in murine placental tissues remain unknown.Therefore, placental mRNA levels
of IL-6, NPY, AgRP, POMC, andCART at different pregnancy stages (gestational days 13, 15, and 18) were analyzed by real time PCR,
as were the effect of IL-6 deficiency (IL-6 knockout mice) on their placental expression. Our results showed that placenta-derived
neuropeptides were regulated by gestational age and IL-6 throughout the second half of mouse pregnancy. These data suggest that
IL-6 may participate in the fine tune control of energy balance during pregnancy by extending its action as a metabolic signal to
the main organ at the fetomaternal interface: the placenta.
1. Introduction
Energy homeostasis, defined as the process whereby body
weight and energy reserves are maintained stable over long
periods of time, is tightly regulated through the complex
interactions of the brain and peripheral organs [1, 2]. Recip-
rocal neural networks within the hypothalamus and the brain
stem act in response to peripheral (metabolic, endocrine,
and neural) signals of metabolic status, matching energy
intake with energy outputs such as basal metabolism, activity,
thermogenesis, and reproduction [3–5].
Afferent endocrine signals projecting to the brain to
encode short- and long-term energy status comprise a wide
variety of tissue-specific signalling molecules including:
(i) adipokines (e.g., leptin, adiponectin, resistin, and
interleukin-6 (IL-6)), secreted by the expanding adipose
tissue; (ii) pancreatic hormones such as insulin and amylin;
(iii) gastrointestinal peptides, such as ghrelin, glucagon-like
peptide I, and peptide YY; and (iv) gonadal and placental
hormones, such as steroids and placental lactogens [2, 6–8].
Several hypothalamic neuronal populations express specific
receptors for these metabolic hormones and communicate
within each other via chemical synapses and the release
of neurotransmitters and neuropeptides, characterized
by having either direct or indirect effects on body weight
regulation and reproductive function [9].
Two opposing cell types in the arcuate nucleus (ARC)
are a relevant example of the integrative nature of the
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hypothalamus in the regulation of energy metabolism and
fertility [10]. One type produces the orexigenic and anabolic
neuropeptide Y (NPY) and agouti-related peptide (AgRP) as
well as gamma-aminobutyric acid (GABA). The other pro-
duces cocaine and amphetamine regulated transcript (CART)
and proopiomelanocortin- (POMC-) derived peptides, such
as alpha melanocyte stimulating hormone (𝛼MSH), that
promote anorexia by inhibiting food intake and increases
catabolic processes. 𝛼MSHmodulates its downstream home-
ostatic signalling via their action at melanocortin recep-
tors MC3R and MC4R, which are antagonized by AgRP
[2]. The coordinated regulation of these neurons and
their efferent projections to key brain regions such as the
paraventricular nucleus (PVN) and the medial preoptic
and lateral hypothalamic area (LH) contributes to regu-
late energy metabolism, gonadotropin-releasing hormone
(GnRH) release, and pituitary-gonadal axis activity [2, 10, 11].
The placenta, a unique and autonomous transient organ,
represents the primary immunological andnutrient transport
barrier between the mother and the fetus. Throughout its
entire lifespan, the placenta is also able to produce as well
as respond to a variety of signalling molecules required
for pregnancy establishment and maintenance but also for
maternal adaptation to pregnancy, as well as fetal growth and
development. Placental secretory factors include among oth-
ers: steroid hormones, growth factors, metabolic hormones
(e.g., leptin [12, 13], adiponectin [14, 15] and resistin [16, 17]),
and pro- and anti-inflammatory cytokines as interleukins-
6 and -10 (IL-6 and IL-10) [18, 19]. Despite the lack of
innervation in this organ, production of energy balance
regulating neuropeptides has been reported in rat [20, 21] and
human [22–25] placenta, where they may play a regulatory
role in placental hormonal secretion that affectsmaternal and
fetal metabolism. However, the physiological relevance and
regulation of these placental neuropeptides remain unclear.
IL-6 is a pluripotent cytokine not only involved in the
immune response, but with multiple relevant effects onmany
different cell types including those of the nervous [26] and
reproductive systems [27, 28]. Recent evidence from our
group [29] and others [30–32] points to the IL-6 system as
a key pathway involved in the central regulation of food
intake and energy metabolism. Hence, centrally (astrocyte-
restricted) [26] and total IL-6 deficiency in mice [33–35] are
associated with increased body weight and adiposity at young
and late ages, while long-term central (intracerebroventric-
ular) but not peripheral IL-6 treatment exerts a restorative
effect on fat mass values [36]. The antiobesity IL-6 action
likely involves enhanced thermogenesis and lipid oxidation
rather than reduced food intake [29, 37–39]. To control this
physiological functions in health [29, 38, 40] and disease
conditions [41], IL-6 engages its widely expressed specific
receptor IL-6 receptor alpha [42] to modulate the expression
of key anabolic and catabolic hypothalamic neuropeptides at
the level of the ARC, PVN, and LH [31, 42, 43].
Our group has recently demonstrated that pregnancy
in the mouse is associated with a progressive increase in
circulating IL-6 levels, while hypothalamic IL-6 and IL-
6Ra expression are depressed [29]. These changes in the
central and peripheral expression of the IL-6 system are
accompanied by specific adaptations in the dam’s hypotha-
lamic circuits governing energy balance, notably at the level
of the ARC and PVN. Major sources of circulating IL-6
during this physiological state include the expanding adipose
tissue as well as the placenta, where it has been related
to disarrangements in maternal-fetal nutrient (i.e., lipid)
transfer in complicated human pregnancies [44]. However,
little is known about the possible influence of this cytokine
on the placental production of energy balance regulating
neuropeptides. Thus, the present study was designed to
determine whether during the second half of pregnancy
NPY, AgRP, POMC, and CART mRNA are expressed and
ontogenetically modulated in the mouse placenta. Using
interleukin-6 knockout mice (IL-6 KO mice) as a model,
the effects of IL-6 deficiency on their gestational pattern of
placental expression were also investigated.
2. Materials and Methods
2.1. Animals. IL-6 deficient mice (B6.129S2-IL-6 tm1 kopf/J,
sourced from Jackson Laboratories) [45] that had undergone
eleven backcrosses to the C57BL/6 background and their
wild-type congenic C57BL/6J controls were purchased from
Jackson laboratories (Charles River, Barcelona, Spain; stock
numbers 002650 and 000664, resp.). After weaning, animals
were housed 5-6 per cage under controlled temperature
conditions (22∘C) and a 12-hour light/dark cycle with free
access to water and rodent chow (2019s, Teklad Global,
Harlan, Spain). Age-matched female WT and IL-6 KO mice
(12 weeks old) were always used for experiments. Ethical
approval was obtained from the University of Santiago de
Compostela Bio-ethics Committee and all the procedures
were conducted according to the regulations of the European
Community for the care and use of experimental animals.
2.2. Experimental Design. To obtain pregnant animals,
twelve-week-old female IL-6 KO or WT mice (𝑛 = 27 and
38, resp.) were mated for three days with stud mice of the
same genotype. Successful matings, as judged by the presence
of a vaginal plug in the early morning (day of occurrence =
day 0 after coitum), were detected in a total of 22 IL-6 KO
mice (81%) and 28WT (74%). On the corresponding day of
pregnancy (day 13, 15, or 18), timed pregnant animals were
anesthetized and after collection of serum samples by cardiac
puncturewere sacrificed by decapitation.About 82 and 61%of
the plugged IL-6KOandWTmicewere pregnant (𝑛 = 18 and
17, resp.), and only one dam of each genotype was excluded
for the analysis due to presence of less than 7 viable (normal
appearing) fetuses (Table 1). Placental samples were removed,
weighed, frozen on dry ice, and stored in –80∘C until further
analysis. At each gestational age analyzed, the number of
fetuses per litter was similar in WT and IL-6 KO groups as
were the weights of conceptuses and placentas (Table 1). We
used 5-6 placentas per experimental group, extracted from
different mothers. All the samples were analyzed individually
and samples were not pooled.
2.3. Serum Assays. Circulating serum levels of interleukin
6 were assayed by ELISA, using a commercial kit (IL-6,
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Table 1: Litter size, weights of dams, conceptuses, and placentas in WT and IL-6 KO dams.
Gestational day Dam weight (g) Conceptus weight (mg) Placental weight (mg) Litter size
WT IL-6 KO WT IL-6 KO WT IL-6 KO WT IL-6 KO
13 29.87 ± 0.57 28.15 ± 0.49
∗
410 ± 64 421 ± 41 77 ± 13 72 ± 9 8.8 ± 0.8 8.5 ± 0.8
(6) (6)
15 34.61 ± 0.72 31.67 ± 0.68
∗
756 ± 54 696 ± 37 101 ± 12 110 ± 11 9.8 ± 0.4 9.2 ± 0.6
(5) (5)
18 38.64 ± 0.69 36.27 ± 0.78
∗
1555 ± 70 1658 ± 74 96 ± 2 85 ± 12 8.5 ± 0.4 7.8 ± 0.3
(5) (6)
Number of dams used in each group is shown in parentheses.
∗
𝑃 < 0.05 versus pregnant WT mice at the same gestational age, two-tailed Student’s 𝑡-test.
Table 2: Primers and probes used for qPCR.
Genes Primer sequences GenBank accesion number Product size (bp)
HPRT
F: 5󸀠-AGCCGACCGGTTCTGTCAT-3󸀠












NM 007427.2 98R: 5󸀠-CGACGCGGAGAACGAGACT-3󸀠
Pb: 5󸀠-CAGAAGGCAGAAGCTTTGGC GG AGGT-3󸀠
CART
F: 5󸀠-CGCAT TCCGATCT ACGAGAAGAA-3󸀠
NM 001081493.2 84R: 5󸀠-CCT GGCCCCTT TCCTCACT-3󸀠
Pb: 5󸀠-CCAAGTCCCCATGTGTGACGCTGGAG-3󸀠.
HPRT F: 5
󸀠-CAGTCCCAGCGTCGTATT-3 NM 013556.2 139
R: 5󸀠-AGCAAGTCTTTCAGTCCTGTC-3󸀠
POMC F: 5
󸀠-TCCATAGACGTGTGAGCTG-3󸀠 NM 139326 174
R: 5󸀠-GACGTACTTCCGGGGATTTT-3󸀠
Abcam, Cambridge, UK) according to the manufacturer’s
instructions.
2.4. Real Time qPCR. Real-time quantitative RT-PCR
(qPCR) analysis was carried out as previously described [46].
Total RNA was obtained by homogenization in TRIZOL
reagent according to the manufacturer’s instructions
(Invitrogen, Barcelona, Spain). First-strand cDNA was
synthesized from 1.5 𝜇g of total RNA in a 30 𝜇L reaction using
200U Maloney murine leukemia virus reverse transcriptase
and randomhexamer primers (Invitrogen, Barcelona, Spain).
qPCR was performed using a Mastercycler EP Realplex real-
time PCR system (Eppendorf). Probe detection (Universal
Master mix; Applied Biosystems) was used for IL-6 [47]
and the neuropeptides NPY, AgRP, and CART expression
analysis [48] (Table 2). SYBR Green was used for POMC
mRNA detection [21] (Luminaris Color HiGreen qPCR
Master Mix; Thermo Fisher Scientific) and was followed by a
melting curve to assure the primers specificity (Table 2).
A standard curve was run in each assay, with an arbitrary
value assigned to the highest standard and corresponding
values to the subsequent dilutions. A nontemplate reaction
was included during each experiment to control for DNA
contamination. Mouse hypoxanthine guanine phosphoribo-
syl transferase (HPRT) was used as control house-keeping
gene [49–51]. The relative expression levels were estimated
using the comparative threshold cycle method [52] and all
samples were normalized againstHPRTexpression values.We
have previously usedHPRTas reference gene in the rat [14, 21]
but not in the mouse placenta. Therefore, we tested whether
the HPRTmRNA levels were stable in placentas frommice of
the same genotype at different gestational ages. HPRTmRNA
expression was similar among gestational age groups, hence
validating its use as reference gene in the present study.
To verify the identity of amplified cDNAs, PCR products
were electrophoresed on a 1.5% agarose gel, which yielded
DNA fragments of the expected length for all mRNAs and
were confirmed by sequencing (data not shown).





















Figure 1: IL-6 levels in serum of WT (C57BL6) mice. 12-week-old
WT mice were time-pregnant and serum IL-6 levels at different
pregnancy stages (13, 15, and 18 days) were assessed by ELISA; 𝑛 =
5-6. Each value represents the mean ± SEM. One-way ANOVA:
∗
𝑃 < 0.05 versus 13 days pregnant.
2.5. Statistical Analysis. Results are given as mean ± SEM.
All data were analyzed using Graph Pad Prism version 6.00
for Windows (GraphPad Software, La Jolla, California USA).
Comparisons between two groups were performed with
unpaired two-tailed Student’s 𝑡-test and one-way analysis of
variance (ANOVA), followed by the Bonferroni post hoc
test, when differences between more than two experimental
groups were analyzed.
3. Results
3.1. Increased Serum IL-6 Levels during Pregnancy in WT
Mice. Firstly, circulating levels of IL-6 were assessed during
pregnancy. As expected [29, 53] serum IL-6 levels increased
as pregnancy progressed although a significant stimulatory
effect was only evident at gestational day 18 from values at
gestational day 13 (𝑃 < 0.05) (Figure 1).
3.2. IL-6 mRNA Expression Is Up-Regulated in the Placenta
of Pregnant WT Mice Throughout Pregnancy. Thereafter we
analyzed the transcriptional profile of placental IL-6 expres-
sion during mouse pregnancy. IL-6 mRNA was detected in
all placentas tested from pregnantWT dams (C57BL6 female
mice) at gestational days 13, 15, and 18. Our data showed that
IL-6 gene expression increased with gestational age in the
mouse placenta, with significantly higher mRNA levels on
days 15 and 18 of pregnancy in comparison to values on day
13 (𝑃 < 0.01 and 𝑃 < 0.001, resp.) (Figure 2).
3.3. NPYmRNAExpression Is Up-Regulated by IL-6Deficiency
in the Mouse Placenta. Next we evaluated the placental NPY
mRNA levels and whether absence of IL-6 might influence
its gestational profile during mouse pregnancy. Although,




























Figure 2: IL-6 mRNA expression in placenta of WT (C57BL6)
mice. 12-week-old WT mice were time-pregnant and placental IL-
6 mRNA levels at different pregnancy stages (13, 15, and 18 days)
were assessed by real-time qPCR; 𝑛 = 5-6. Relative mRNA levels
were normalized to 13 days pregnant mice values as 1. Each value
represents the mean ± SEM. One-way ANOVA: ∗∗𝑃 < 0.01 versus
13 days pregnant mice values.
increased NPY mRNA expression at gestational day 15 in
relation to the other stages of pregnancy studied, no statistical
difference was observed (Figure 3(a)). On the contrary, in
absence of IL-6, placental NPY mRNA expression remained
unchanged between 13 and 15 days of pregnancy reaching the
highest values at the end of the gestational period (𝑃 < 0.01)
(Figure 3(b)).
3.4. Lack of IL-6 Does Not Affect AgRP mRNA Expression
in the Mouse Placenta. AgRP mRNA was expressed in the
mouse placenta at all gestational ages assessed but showed
a slightly different profile during pregnancy from that of
NPY.Thus, AgRP mRNA content in the placenta of pregnant
WT mice did not change significantly from 13 to 18 days of
pregnancy (Figure 4(a)), being unaffected by IL-6 deficiency
(Figure 4(b)).
3.5. POMC mRNA Expression Is Down-Regulated by IL-6
Deficiency in the Mouse Placenta. Placental POMC mRNA
expression in WT mice was markedly reduced at the latest
pregnancy stage (gestational day 18, 𝑃 < 0.05), while
it remained unchanged from 13 to 15 days of pregnancy
(Figure 5(a)). However, IL-6 KO mice showed a significantly
(𝑃 < 0.05) reducing trend for placental POMC mRNA
content from gestational days 13 to 18 (Figure 5(b)).
3.6. CART mRNA Expression Is Up-Regulated by IL-6 Defi-
ciency in the Mouse Placenta. Finally, we studied the tran-
scriptional profile of CART expression in the placenta of
WT and IL-6 KO mice during pregnancy. Our data showed
that this catabolic neuropeptide had a constitutive and fairly
constant expression in the placenta of WT mice throughout
























































Figure 3: NPYmRNA expression in placenta ofWT and IL-6 KOmice. 12-week-oldWT and IL-6 KOmice were time-pregnant and placental
NPYmRNA levels in (a)WT and (b) IL-6 KOmice at different pregnancy stages (13, 15, and 18 days) were assessed by real-time qPCR; 𝑛 = 5-6.
Within each genotype, relative mRNA levels were normalized to 13 days pregnant mice values as 1. Each value represents the mean ± SEM.





















































Figure 4: AgRP mRNA expression in placenta of WT and IL-6 KO mice. 12-week-old WT and IL-6 KO mice were time-pregnant and
placental AgRP mRNA levels in (a) WT and (b) IL-6 KO mice at different pregnancy stages (13, 15, and 18 days) were assessed by real-time
qPCR; 𝑛 = 5-6. Within each genotype, relative mRNA levels were normalized to 13 days pregnant mice values as 1. Each value represents the
mean ± SEM.
pregnancy (Figure 6(a)). A similar pattern was observed in
the placentas from IL-6 KO mice until gestational day 18,
when the highest levels of placental CARTmRNA expression
were reached (𝑃 < 0.01) (Figure 6(b)).
4. Discussion
Pregnancy is now recognized as a state of adaptive, low-
grade-inflammation induced by a progressive increase of
circulating levels inflammatory mediators such as cytokines,
chemokines, and acute-phase reactants [53, 54]. Cytokines,
central players of this inflammatory response, are secreted by
the immune cells and adipocytes but also by placental cells
[55]. Placental cytokine production and action are crucial
to control trophoblast implantation, embryo development,
and feto-maternal tolerance [55]. However, once pregnancy
is established, the physiological relevance of most placental
cytokines remains unclear.
Proinflammatory cytokines, such as IL-6, TNF alpha,
and IL-1, are known to negatively influence peripheral lipid
























































Figure 5: POMC mRNA expression in placenta of WT and IL-6 KO mice. 12-week-old WT and IL-6 KO mice were time-pregnant and
placental POMC mRNA levels in (a) WT and (b) IL-6 KO mice at different pregnancy stages (13, 15, and 18 days) were assessed by real-time
qPCR; 𝑛 = 5-6. Within each genotype, relative mRNA levels were normalized to 13 days pregnant mice values as 1. Each value represents the





















































Figure 6: CART mRNA expression in placenta of WT and IL-6 KO mice. 12-week-old WT and IL-6 KO mice were time-pregnant and
placental CART mRNA levels in (a) WT and (b) IL-6 KO mice at different pregnancy stages (13,15, and 18 days) were assessed by real-time
qPCR; 𝑛 = 5-6. Within each genotype, relative mRNA levels were normalized to 13 days pregnant mice values as 1. Each value represents the
mean ± SEM. One-way ANOVA: ∗𝑃 < 0.05 versus 13 days pregnant mice of respective genotype.
and glucose metabolism. Hence, by secreting these immune
factors, the placenta may enhance the contribution made
by adipose tissue to induce maternal insulin resistance and
ensure a proper glucose transfer to the growing fetus. In this
study, we found increased expression of IL-6 mRNA in the
mouse placenta during gestation. These results are in agree-
ment with previous reports of an enhanced IL-6 placental
production during the latest stages of rat [54] and human
pregnancies [56]. To our knowledge, the present work is the
first one to determine the ontogenetic profile of IL-6 mRNA
levels in the mouse placenta. In fact, De and coworkers [57]
showed high levels of placental IL-6 bioactivity but failed to
demonstrate its constitutive transcriptional expression in this
mouse reproductive organ. The reason for this discrepancy
may be the different methodologies employed, since in this
previous study IL-6mRNA levelsweremeasured byNorthern
blot while we used a more sensitive technique, RT-qPCR.We
[29] and others [53, 58] have previously found elevated IL-
6 serum and adipose tissue mRNA levels during mouse late
pregnancy. Our data do not allow us to determine the relative
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contribution of both tissues to the amount of this cytokine
present in maternal circulation, but the similar pattern of IL-
6 mRNA overexpression in both tissues suggests that both
could be a source of circulating IL-6 in pregnancy.
Our group has recently shown that, in addition to
its peripheral metabolic effects, IL-6 modulates the cen-
tral mechanisms associated to maternal hyperphagia and
increased adiposity in the pregnantmouse [29]. Although the
transcriptional expression of its hypothalamic neuropeptide
targets NPY, AgRP, POMC, and CART in the human [24,
25] and rat placenta [20] is well established, whether they
are also placentally produced and regulated by IL-6 during
mouse pregnancy remains unknown. In order to clarify this
issue, we determined the placental mRNA expression of
these energy balance regulating neuropeptides throughout
pregnancy (from gestational days 13 to 18) in WT and IL-6
deficient mice.
The results of the present study revealed a similar tran-
scriptional regulation of ARC neuropeptides in the mouse
placenta from that previously reported in the hypothalamus
[29]. Thus, POMC mRNA levels were reduced from gesta-
tional days 13 to 18, while the expression of the orexigenic
and anabolic neuropeptides NPY/AgRP remains unchanged.
A similar absence of relation between gestational age and
placental NPY mRNA content has been shown in other
species [20, 25]. On the contrary, the placental ontogenetic
expression of the melanocortin system members POMC and
AgRP seems to be a rather controversial issue. Therefore,
some studies reported a decrease in AgRP mRNA levels with
gestational age and no change in POMC levels, whilst others
showed an upregulated mRNA expression of both neuropep-
tides in human [24] and rat placentas [20, 21]. As far as we are
aware, the mRNA expression of CART has been previously
examined neither in human nor in murine placental tissues.
In this sense, recent data from our group demonstrated that
themRNA levels of this catabolic and anorectic neuropeptide
are markedly increased in the rat placenta at term [20, 21].
However, in the present study we failed to detect any change
in CART gene expression throughout mouse pregnancy. The
reason for this discrepancy is unclear but itmight reflect some
biological differences between species.
Another novel finding of the present study is the fact that
IL-6, acting on an autocrine or paracrine manner, modulates
the placental expression of classical ARC energy balance reg-
ulatory peptides, as shown by IL-6 KOmice data. Thus, NPY
and CART mRNA levels are upregulated by IL-6 deficiency
at late pregnancy while POMC gene expression is downregu-
lated in placentas from 15-day pregnant IL-6 KOmice. These
results indicate that, during the third week of pregnancy,
lack of IL-6 settles an anabolic milieu in the mouse placenta
by reciprocally modulating the transcriptional expression of
neuropeptides known to either promote, NPY, or repress,
POMC, net energy gain. As we have previously demonstrated
in the hypothalamus of the mouse in late pregnancy a lack
of IL-6 upregulates NPY/AgRP mRNA levels in the ARC;
it seems that IL-6 deficiency during late pregnancy exerts
a stimulatory effect on NPY gene transcription whatever is
its source. However, the results obtained regarding placental
CART/POMC gene expression were somewhat unexpected.
Increased hypothalamic CART or POMC production has
been reported after endotoxemic challenge or central admin-
istration of other well-known proinflammatory cytokines
as IL-1 [59, 60]. In addition, exercise-induced hypothala-
mic IL-6 and IL-10 in obese rats [61] and IL-6 astrocyte-
targeted overexpression in female mice have been shown
to increase POMC expression in the ARC [62]. Conversely,
total knockout of IL-6 in mice restored to virgin values the
reduced POMC mRNA levels in the ARC of late pregnant
mice, probably reflecting a compensatorymechanism exerted
by other factors [29]. On the contrary, the data reported
herein indicate that, during the second half of pregnancy, this
compensatory effect on POMC gene expression is not settled
in the mouse placenta. Considering the above mentioned
results and the fact that CART and POMC are colocalized in
the ARC, a similar pattern of placental expressionmight have
been expected for both neuropeptides. However, we have
not performed in situ hybridization or immunohistochemical
studies to characterize cellular distribution of CART and
POMC in placental tissue. Therefore, we cannot exclude the
possibility that different placental cell types could produce
these neuropeptides and respond to absence of IL-6 in a
different manner. In fact, with respect to their hypothalamic
regulation, it is worth to mention that CART mRNA has
been reported in a number of hypothalamic cell populations
besides the ARC, where its expression has been shown to be
differentially modulated from that of POMC in response to
endotoxin challenge [63].
Finally, in relation to the previous point, it is important
to take into account that the experimental approach used in
the current study was designed to assess, during the second
half of pregnancy, global changes in IL-6, and main energy
regulating neuropeptides gene expression in the mouse pla-
centa. Additionally, the IL-6 deficient mouse was chosen to
address the influence of total absence of endogenous IL-6 on
this setting. However, the murine placenta consists of three
mayor cell layers of maternal or placental origin: the outer
maternal decidua, the middle junctional zone, composed
of fetoplacental trophoblast cells, and the inner labyrinth
zone [64]. Therefore further in vitro studies involving either
decidual or trophoblast cells in culture would be helpful to
determine the ability of each cell population to produce and
secrete these neuropeptides and confirm the contribution of
IL-6 to their transcriptional modulation.
Whatever is the case; these results of the current study
suggest that IL-6, by exerting a direct or indirect regulatory
action in the transcriptional control of NPY, CART, and
POMC expression, may play a role in the homeostatic
response to energy availability in mouse placenta. Finally,
whether placental neuropeptide protein levels correlate with
the ontogenetic neuropeptide mRNA pattern herein shown
will merit further investigation.
5. Conclusions
In summary, we demonstrate that as in other species, the
classical hypothalamic neuropeptidergic systems involved
in energy homeostasis are present in the mouse placenta.
8 International Journal of Endocrinology
These central signals display a specific ontogenetic expression
pattern in absence of IL-6 with major changes settled in
placentas at term. Thus, our results suggest that IL-6, a well-
known immune and metabolic modulating factor, might
modulate their transcriptional expression by acting on an
autocrine or paracrine manner. Collectively, these results
suggest that during an energetic challenging condition such
as pregnancy IL-6 may also extend its action as a metabolic
signal to the main organ at the maternal-fetal interface: the
placenta.
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